Zyprexa® Relprevv™ Patient Care Program

Part of paid clinical trials in Blue Bell, Pennsylvania.

Sponsor
Eli Lilly and Company
Study ID
NCT01088386
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The goal of the Zyprexa Relprevv Patient Care Program is to mitigate the risk of negative outcomes associated with Zyprexa Relprevv post-injection delirium/sedation syndrome (PDSS).

Key Dates

Start date
Mar 3, 2010
Status verified
Jan 2026
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026

Study Design

Enrollment
4,000 participants (estimated)

Arms

  • Arm: Patients
    All patients who will be receiving Zyprexa Relprevv must be enrolled into the Zyprexa Relprevv Patient Care Program

Primary Outcome Measure

Incidence per injection and per patient of post-injection delirium/sedation syndrome (PDSS) events [ Time Frame: Baseline to end of study ]

Locations (1)

FacilityCityStateZIPSite coordinators
United BioSource CorporationBlue BellPennsylvania19422-

Find similar trials in Blue Bell, PA

By condition
Schizophrenia
By specialty
PsychiatryMental healthBehavioral health
By research site
United BioSource Corporation· Blue Bell, PA

Related Studies